Seattle Genetics (NASDAQ:SGEN) Price Target Raised to $186.00 at BMO Capital Markets

Share on StockTwits

Seattle Genetics (NASDAQ:SGEN) had its price objective hoisted by BMO Capital Markets from $174.00 to $186.00 in a research report sent to investors on Tuesday, The Fly reports.

Several other brokerages have also recently commented on SGEN. William Blair restated a buy rating on shares of Seattle Genetics in a report on Friday, April 3rd. Oppenheimer increased their price objective on shares of Seattle Genetics from $175.00 to $200.00 and gave the stock an outperform rating in a report on Friday, June 26th. Barclays reaffirmed a hold rating on shares of Seattle Genetics in a research note on Sunday, May 3rd. Needham & Company LLC increased their price target on shares of Seattle Genetics from $163.00 to $188.00 and gave the company a buy rating in a research note on Tuesday. Finally, Zacks Investment Research lowered shares of Seattle Genetics from a buy rating to a hold rating and set a $132.00 price target for the company. in a report on Wednesday, April 15th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Seattle Genetics presently has an average rating of Buy and a consensus target price of $147.42.

Shares of SGEN stock opened at $169.92 on Tuesday. The company has a market capitalization of $28.45 billion, a P/E ratio of -90.38 and a beta of 1.42. Seattle Genetics has a 12-month low of $63.02 and a 12-month high of $175.64. The firm has a 50-day moving average price of $158.02 and a 200 day moving average price of $127.98.

Seattle Genetics (NASDAQ:SGEN) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.17). Seattle Genetics had a negative net margin of 32.81% and a negative return on equity of 16.51%. The firm had revenue of $234.51 million during the quarter, compared to the consensus estimate of $207.59 million. During the same quarter last year, the firm posted ($0.08) EPS. The business’s revenue was up 20.1% on a year-over-year basis. As a group, equities research analysts predict that Seattle Genetics will post -2.8 earnings per share for the current year.

In related news, EVP Jean I. Liu sold 9,877 shares of the company’s stock in a transaction on Friday, June 19th. The shares were sold at an average price of $165.00, for a total value of $1,629,705.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker sold 500,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $158.50, for a total value of $79,250,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 700,756 shares of company stock valued at $110,414,053. 31.10% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Capital World Investors acquired a new stake in shares of Seattle Genetics during the first quarter worth about $33,737,000. Nomura Asset Management Co. Ltd. raised its holdings in shares of Seattle Genetics by 18.5% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 21,469 shares of the biotechnology company’s stock worth $2,453,000 after acquiring an additional 3,356 shares during the period. Mackenzie Financial Corp bought a new stake in Seattle Genetics in the 1st quarter valued at $379,000. Baird Financial Group Inc. boosted its stake in Seattle Genetics by 2.5% in the 1st quarter. Baird Financial Group Inc. now owns 4,300 shares of the biotechnology company’s stock worth $496,000 after purchasing an additional 103 shares during the period. Finally, US Bancorp DE increased its holdings in Seattle Genetics by 52.9% during the 1st quarter. US Bancorp DE now owns 11,359 shares of the biotechnology company’s stock worth $1,311,000 after purchasing an additional 3,932 shares in the last quarter. Institutional investors own 94.33% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.

Featured Article: How to interpret Moving Average Convergence Divergence (MACD)

The Fly

Analyst Recommendations for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

B. Riley Comments on Novavax, Inc.’s Q2 2020 Earnings
B. Riley Comments on Novavax, Inc.’s Q2 2020 Earnings
Freehold Royalties Ltd  Director Tom Mullane Purchases 10,000 Shares
Freehold Royalties Ltd Director Tom Mullane Purchases 10,000 Shares
Rapid7  Upgraded to “Hold” at BidaskClub
Rapid7 Upgraded to “Hold” at BidaskClub
Repligen  Given “Buy” Rating at HC Wainwright
Repligen Given “Buy” Rating at HC Wainwright
B. Riley Weighs in on Ramaco Resources Inc’s Q2 2020 Earnings
B. Riley Weighs in on Ramaco Resources Inc’s Q2 2020 Earnings
Rotork  Given New GBX 230 Price Target at Credit Suisse Group
Rotork Given New GBX 230 Price Target at Credit Suisse Group


 
© 2006-2020 Zolmax.